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Abstract: CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in decreased
enzyme activity are common in the CYP2C9 gene and this, combined with narrow therapeutic indices
for several key drug substrates, results in some important issues relating to drug safety and efficacy.
CYP2C9 substrate selectivity is detailed and, based on crystal structures for the enzyme, we describe
how CYP2C9 catalyzes these reactions. Factors relevant to clinical response to CYP2C9 substrates
including inhibition, induction and genetic polymorphism are discussed in detail. In particular, we
consider the issue of ethnic variation in pattern and frequency of genetic polymorphisms and clinical
implications. Warfarin is the most well studied CYP2C9 substrate; recent work on use of dosing
algorithms that include CYP2C9 genotype to improve patient safety during initiation of warfarin
dosing are reviewed and prospects for their clinical implementation considered. Finally, we discuss a
novel approach to cataloging the functional capabilities of rare ‘variants of uncertain significance’,
which are increasingly detected as more exome and genome sequencing of diverse populations
is conducted.
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1. Introduction
The cytochrome P450 2C (CYP2C) subfamily comprises four enzymes: CYP2C8, CYP2C9,
CYP2C18 and CYP2C19. Of these, CYP2C9 is the most abundantly expressed and contributes to
drug metabolism to the greatest extent. Indeed, CYP2C9 accounts for approximately 20% of total
hepatic P450 protein, based on mass spectrometry quantitation [1]. Significant expression additionally
occurs in the gastrointestinal tract [2]. After CYP3A4 and CYP2D6, CYP2C9 is the next most important
cytochrome P450 in terms of the numbers of therapeutic agents oxidized, contributing to the
metabolism of approximately 15% of all drugs that are subject to P450-catalyzed biotransformation [3].
Importantly, as discussed below in Sections 2 and 4, CYP2C9 is the major enzyme responsible for
the metabolic clearance of several clinically used drugs that have a narrow therapeutic index. Thus,
inter-individual variability in CYP2C9 protein expression and activity may impact the efficacy and
safety of drug treatment. In this regard, the CYP2C9 protein content of human liver microsomes
(HLM) varies by an order of magnitude [1] and activity in vivo, measured as the tolbutamide urinary
metabolic ratio, was similarly found to vary by an order of magnitude in a group of healthy subjects
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that excluded poor metabolizers [4]. The occurrence of drug–drug interactions (DDIs), arising from
inhibition or induction of CYP2C9, and genetic polymorphism further increase the extent of population
variability in enzyme activity in vivo [5–8]. Here, we review aspects of CYP2C9 with particular
reference to structure–function relationships and pharmacogenomics. Additional information on
this subject area is available from several other recent review articles on various P450s that include
coverage of CYP2C9 [9–11].
2. CYP2C9 Substrate Selectivity
The identification of CYP enzyme selective substrate and inhibitor ‘probes’ along with the
availability of heterologously expressed recombinant human CYP enzymes that occurred over the last
three decades has facilitated the development of reaction phenotyping procedures for characterizing
the contribution of specific enzymes to a metabolic pathway. Of the various reaction phenotyping
approaches adopted [12], the use of enzyme-specific inhibitors provides the least ambiguous means
of characterizing the contribution of a CYP enzyme(s) to a metabolic pathway when HLM and
hepatocytes are employed as the enzyme source. Identification of sulfaphenazole as a highly selective
CYP2C9 inhibitor [13–15] has proved invaluable for determining the contribution of this enzyme to
the metabolism of any given compound [5].
CYP2C9 contributes to the oxidation of a large number of drugs and also metabolizes a number
of endogenous compounds, for example arachidonic acid, linoleic acid, and non-drug xenobiotics
(e.g., galangin, methiocarb, pyrene, safrole, sulprofos and ∆-9-tetrahydrocannabinol). The range of
substrates and their structures has been reviewed in detail previously [5,7,16,17]. The majority of
substrates are weakly acidic compounds, although CYP2C9 also catalyzes the N-demethylation of a
number of basic drugs (e.g., amitriptyline, fluoxetine and zopiclone).
Table 1 shows representative examples of drugs for which CYP2C9 is responsible for >25%
of metabolic clearance. Sulfonylurea oral hypoglycemic agents, non-steroidal anti-inflammatory
drugs (NSAIDs), and coumarin anticoagulants feature prominently. However, CYP2C9 contributes
significantly to the metabolic clearance of drugs from other therapeutic classes, including the
widely used anticonvulsant phenytoin [18,19], the diuretic torsemide [20] and the antihypertensive
losartan [21]. In the latter case, CYP2C9 is the primary enzyme responsible for the conversion of
losartan to its pharmacologically active metabolite E-3174.
Table 1. Representative examples of drugs for which CYP2C9 is responsible for >25% of
metabolic clearance.
Drug Class Drugs
Anticoagulants Acenocoumarol, phenprocoumon, S-warfarin
Antihypertensives Irbesartan, losartan
NSAIDs Celecoxib, diclofenac, etodolac, ibuprofen, indomethacin,lornoxicam, mefenamic acid, suprofen, tenoxicam
Oral hypoglycemic agents Chlorpropamide, glibenclamide, gliclazide, glimepiride,nateglinide, tolbutamide
Miscellaneous Bosentan, fluvastatin, mestranol, phenytoin, torsemide
Taken from references [5–7,16,17]. NSAIDs: nonsteroidal anti-inflammatory drugs.
Several of the drugs listed in Table 1 have been employed as substrate ‘probes’ to measure
CYP2C9 activity in vitro and in vivo. Diclofenac 4′-hydroxylation, S-flurbiprofen 4′-hydroxylation,
losartan carboxylation, phenytoin 4′-hydroxylation, tolbutamide and torsemide tolylmethyl
hydroxylation, and S-warfarin 7-hydroxylation activities have been used to assess CYP2C9 activity
in vitro, with HLM, human hepatocytes and recombinant protein as enzyme sources, and as probe
substrates in studies investigating drug and chemical inhibition of CYP2C9 and the influence of
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genetic polymorphism on CYP2C9 activity [5,6,22]. Each has its advantages and disadvantages,
although tolbutamide and the structurally related torsemide have been proposed as a convenient
compromise [13,23]. Most of the compounds utilized as substrates in vitro have similarly been
employed, either individually or as part of a ‘cocktail’ of CYP enzyme substrate probes, to assess
factors (genetic polymorphism, drug–drug interactions, disease states) that affect CYP2C9 activity
in vivo [6,24]. An assessment of the drugs used as part of a ‘cocktail’ to assess CYP2C9 activity
in vivo (diclofenac, flurbiprofen, losartan, tolbutamide and warfarin) recommended tolbutamide [24],
although this drug is no longer available for clinical use in several countries. Recent studies on
cocktails suitable for phenotype determination in resource-limited regions proposed losartan as the
CYP2C9 activity probe [25], though a systematic evaluation of this approach similar to that performed
previously [24] is still needed. A practical, though often overlooked, alternative is to use warfarin as
the in vivo probe, but to administer vitamin K concomitantly to minimize safety concerns [26].
3. CYP2C9 Structure–Function
Knowledge of CYP2C9 structure–function relationships is well advanced due to the availability
of X-ray crystal structures along with data from site-directed mutagenesis studies. Figure 1 provides
an overview of the CYP2C9 structure with substrate recognition sites (SRS) indicated. Notably,
an X-ray crystal structure of CYP2C9 complexed with flurbiprofen (Protein Data Bank code 1R90)
in a catalytically favorable orientation has provided important insights into the binding of acidic
substrates [27]. Specifically, this structure demonstrates a pivotal role for Arg108 in the binding of
flurbiprofen. The conformational flexibility of the helix B to helix C loop region (see below) allows
Arg108 to form a salt-bridge with the carboxylate group of flurbiprofen and additionally hydrogen
bond with Asn289 and Asp293 on helix I, which serves to stabilize the conformation of Arg108 within
the active site. Flurbiprofen packs into a hydrophobic cleft adjacent to helix-I that is formed by specific
residues in SRS 1 (Val113, Phe114), 2 (Leu208), 3 (Val237, Met240), 4 (Gly296, Ala297), and 5 (Leu366).
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Figure 1. CYP2C9 structure showing substrate recognition sites (SRS) according to Gotoh [28]. The SRS
are denoted by arrows: SRS1 (red), SRS2 (green), SRS3 (blue), SRS4 (yellow), SRS5 (orange) and SRS6
(magenta). The secondary structure elements of the rest of the protein are shown in white. The haem
molecule is shown in ball and sticks ith C, O, N, and Fe atoms in cyan, red, blue, and orange,
respectively (from [29]). Reproduced with permission from Nair, P.C.; McKinn , R.A.; Miners, J.O.
Cytochrome P 50 structure–function: insights from molecular dynamics simulations. Drug Metab. Rev.
2016, 48, 434–452; published by Taylor and Francis, 2016.
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Site-directed mutagenesis data are consistent with a pivotal role for Arg108 in the binding
of acidic substrates. Substitution of Arg108 with Ala, Glu or Phe greatly reduced or abolished
the metabolism of diclofenac and S-warfarin, whereas the Arg108Glu mutation had a negligible
effect on the 1-hydroxylation of the unsubstituted polycyclic aromatic hydrocarbon pyrene and the
4-hydroxlation and dealkylation of propranolol (a basic compound) [30–32]. Confirmation of the
roles of Val113 and Phe114 in stabilizing substrate binding via π–π interactions was demonstrated
by reduced or complete loss of S-warfarin and diclofenac metabolism following substitution with
Leu or Ile [33,34]. Lesser inhibition was observed with lauric acid, which lacks an aromatic group.
Finally, mutagenesis of Asp293 to Ala, Asn or Val decreased activity towards dextromethorphan,
diclofenac, pyrene, tolbutamide and S-warfarin in a substrate-independent manner due to reduced
protein stability rather than an effect on substrate binding [32,35]. However, conservative replacement
of Asp293 with Glu had only a minor effect on substrate binding and turnover [35].
In addition to the 1R90 structure described above, CYP2C9 X-ray crystal structures, with and
without bound warfarin (PDB codes 1OG5 and 1OG2), have been solved [36]. Interestingly, in the
10G2 structure, warfarin was bound in the distal end of the active site cavity, possibly in an access
channel [37], in an unproductive position some 10 Å from the heme iron. However, the constructs
used to determine these structures were more extensively modified compared to that used to
generate 1R90 [27]. In contrast to 1R90, Arg108 was oriented away from the active site in these
structures. The non-involvement of Arg108 in the binding of ‘compound 1’, a sulfone derivative
from a drug discovery project, has similarly been reported for the X-ray crystal structure of CYP2C9
complexed with compound 1 (PDB code 4NZ2) [38]. As speculated by the authors of the latter
study, conformational differences observed between the various CYP2C9 structures may arise
from the mutations engineered into the proteins to facilitate crystallization, or possibly represent
a dynamic equilibrium.
In the latter regard, it is now well recognized that conformational flexibility (plasticity) is a
feature of P450 proteins. Comparison of X-ray crystal structures reported for some CYP enzymes
with different bound ligands together with molecular dynamics (MD) simulations demonstrate that
dramatic ligand-induced conformational changes may follow substrate or inhibitor binding [29].
The transition from an ‘open’ to ‘closed’ state that occurs upon ligand binding may result in changes
in the active site volume, the spatial positioning of backbone amino acids, and amino acid side-chain
conformation. Notably, MD simulations of flurbiprofen-bound CYP2C9 showed the B–C loop
region located approximately 20 Å away from the heme compared to the conformation adopted
by the unliganded structure [39]. Given the inherent flexibility of CYP2C9 and other P450 proteins,
different chemical classes of substrates and inhibitors may adopt different binding modes within
the active site. For example, pharmacophore modeling data are consistent with distinct binding
modes for acidic and ‘atypical’ basic (amine-containing) CYP2C9 substrates [16]. Thus, predicting the
effects of genetic polymorphism on substrate and inhibitor binding (and hence kinetics) may not be
straightforward using static X-ray crystal structures, particularly when the mutation is located outside
of the active site (see Section 5.3 for further discussion).
4. Clinical Relevance of CYP2C9
4.1. Clinically Relevant Substrates
The emphasis in this section is on key CYP2C9 substrates used therapeutically, especially those
where drug interactions and effects of genetic polymorphisms may affect treatment outcomes.
Important substrates in terms of narrow therapeutic index and predominant metabolism by CYP2C9
are the coumarin anticoagulants, especially warfarin, and acenocoumarol, most sulfonylureas and
phenytoin (Table 1).
Coumarin anticoagulants including warfarin are among the most widely prescribed drugs
worldwide and are used to prevent thromboembolism in at risk individuals. Warfarin is the most widely
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used member of this class, but two other compounds with coumarin structures, acenocoumarol and
phenoprocoumon, are preferred in some countries. All three drugs target the enzyme vitamin K
epoxide reductase and require individualised dosing that is achieved by optimization of the coagulation
rate (target International Normalized Ratio of 2–3 in most cases) following the start of treatment with
titration of dose to achieve the required endpoint. The need to titrate dose arises in part due to
interindividual variability in metabolism. An important role for CYP2C9 in the metabolism of the
more active warfarin enantiomer, S-warfarin, is well established [40]. Though other P450s contribute
to both R- and S-warfarin metabolism, data from studies concerned with drug–drug interactions and
pharmacogenetics suggest that CYP2C9 is the key determinant of metabolism of this drug in vivo [41].
Acenocoumarol is also mainly metabolised by CYP2C9 [42], but there are some differences to warfarin
with respect to rate of metabolism and enantiomer selectivity [43]. Phenprocoumon is also a CYP2C9
substrate but there appears to be a larger contribution to its oxidative metabolism from CYP3A4 than for
the other two coumarin anticoagulants [44]. For the coumarin anticoagulants, there is a risk of serious
bleeding if plasma drug concentrations are too high due, for example, to a drug–drug interaction
or genetic polymorphism. Frequent measurement of international normalized ratio (INR) and dose
adjustment mitigates the risk. Increasingly, direct acting oral anticoagulants such as dabigatran and
rivoroxaban are being used in place of coumarin anticoagulants [45]. These are entirely different drugs
to the coumarin anticoagulants with respect to their mechanism of action and there is no role for
CYP2C9 in their metabolism.
Many of the older studies on CYP2C9 used tolbutamide as a model compound [5]. However,
this first-generation sulfonylurea is now rarely prescribed, with second-generation compounds used
widely instead for the treatment of type II diabetes [46]. These latter compounds are structurally
related to tolbutamide but show some differences with respect to P450-mediated metabolism. The most
widely used second-generation sulfonylurea in a number of different countries is gliclazide [47],
which appears to be predominantly metabolized by CYP2C9. However, CYP2C19 also has at least a
minor role in the metabolism of this compound [48], and some data suggest that this is also the case for
glipizide [49]. As reviewed recently [50], with all the sulfonylureas, there is risk of hypoglycaemia if
plasma drug concentrations are not maintained within the normal therapeutic range, and low CYP2C9
activity due to enzyme inhibition or genetic polymorphism may increase this risk.
On the basis of a similar chemical inhibitor sensitivity pattern to that for warfarin and tolbutamide,
hydroxylation of phenytoin to p-HPPH was also demonstrated to be CYP2C9-mediated [51].
As with some of the sulfonylureas referred to above, there is also a minor contribution from
CYP2C19. Phenytoin has a narrow therapeutic index and toxicity is associated with a variety of
neurological symptoms; high plasma concentrations may additionally contribute to hepatic and skin
toxicity reactions.
NSAIDs including diclofenac, flurbiprofen and ibuprofen are also well established CYP2C9
substrates. However, this group of drugs undergoes metabolism by other CYP enzymes including
CYP2C8 and CYP3A4, often to different metabolites to those formed by CYP2C9, together with direct
glucuronidation. For some other drugs including valproic acid and bosentan, metabolism by CYP2C9
appears important to treatment outcome under certain circumstances and this will be considered below
in more detail. The angiotensin II receptor antagonist losartan is another interesting CYP2C9 substrate.
An active carboxylic acid metabolite E-3174 is generated by CYP2C9 oxidation of the alcohol moiety.
E-3174 has higher antagonist activity and a longer half-life than the parent drug [21]. Certain other
sartan family members namely ibresartan [52] and, to a more limited extent candesartan [53] and
valsartan [54], are also CYP2C9 substrates, but active metabolites are not generated. Other sartan
family members are not metabolized by P450 [55]. In addition to prescribed drugs, CYP2C9 contributes
to arachidonic acid metabolism with a role in the formation of epoxyeicosatrienoic acids (EETs) [56].
This pathway, which is not unique to CYP2C9, has nevertheless prompted a number of studies in
relation to CYP2C9 genotype as a risk factor for several diseases (see Section 6.5).
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4.2. CYP2C9 Inducers and Inhibitors
CYP2C9 is subject to inhibition by a wide range of drugs, both in vitro and in vivo [5,6].
Some of these are general P450 inhibitors such as cimetidine and ketoconazole and will not be
considered in detail. However, there are a range of more specific and potent inhibitors that are useful
in laboratory-based investigations and clinical trials, particularly sulfaphenazole which, as noted
previously, is used to establish a role for CYP2C9 in metabolism in vitro. Other inhibitors include
fluconazole, voriconazole and amiodarone. Amiodarone is often prescribed in combination with
warfarin due to its antiarrhythmic effects. The DDI risk of this combination is well recognized [57],
necessitating a change in warfarin dose of 6–65% [58]. The narrow therapeutic index of a range of
widely prescribed CYP2C9 substrates discussed above means that there is a risk of clinically significant
DDIs when these drug substrates and inhibitors are combined.
CYP2C9 is inducible by mechanisms involving various nuclear receptors including PXR, CAR,
the glucocorticoid receptor, the estrogen receptor and the vitamin D receptor. Evidence for this range
of induction mechanisms is provided by descriptions of some important DDIs involving induction,
the existence of a variety of nuclear receptor response elements in the CYP2C9 promoter region and
data from a range of in vitro studies on both primary hepatocytes and cell lines such as HepG2.
Induction of CYP2C9 expression by individual ligands may involve more than one of the nuclear
receptors and therefore several different promoter binding sites.
PXR is the best characterized nuclear receptor in terms of a role in CYP2C9 induction. In particular,
clinical reports of rifampicin interactions with drugs now known to be CYP2C9 substrates emerged
in the 1970s [59,60]. Rifampicin is a well-established ligand for human PXR [61,62] and other
ligands identified soon after discovery of PXR include hyperforin, clotrimazole and nifedipine [61].
Phenobarbital is usually considered to interact with genes via another nuclear receptor (CAR),
but it also binds to PXR and appears to be able to induce P450 expression via this receptor [63].
The CYP2C9 upstream region includes several CAR response elements and it was thought originally
that CAR-related induction of CYP2C9 might be more important than PXR-related induction [64,65].
However, it now appears that CAR-specific inducers such as CITCO have a limited effect on CYP2C9
expression and that phenobarbital induction of CYP2C9 may involve mainly PXR [66]. On the basis
of studies using both primary hepatocytes and in silico predictions, a wide range of structurally
different drugs are known to bind to PXR and induce CYP3A4 activity including certain penicillins,
cephalosporins and macrolides [67,68]. Similar studies specifically on CYP2C9 induction are more
limited but are in general agreement with those for CYP3A4 [69]. Predictions that antimicrobials such
as dicloxacillin and flucloxacillin are PXR inducers relevant to CYP2C9 expression are in line with data
on drug–drug interactions for warfarin [70,71].
The estrogen receptor also appears to be a regulator of CYP2C9 expression, but in this
case estradiol and ethinylestradiol interact with the receptor and decrease gene expression with
antiestrogens including tamoxifen increasing expression [72]. This slightly unexpected finding is
consistent with clinical data on metabolism of the CYP2C9 substrate losartan where women taking
oral contraceptives show slower metabolism than other women [73].
5. CYP2C9 Genetic Polymorphisms
5.1. Background
Evidence for the existence of a polymorphism affecting metabolism of the anti-diabetic drug
tolbutamide was first reported in 1978 [74], but at that time it was thought that this might be related
to the debrisoquine (CYP2D6) polymorphism. Subsequent studies showed that genetic regulation of
tolbutamide metabolism was distinct from debrisoquine metabolism [15]. In parallel with these studies,
an enzyme that could oxidize tolbutamide was cloned and later named CYP2C9 [75,76]. Analysis of
CYP2C9 cDNA sequences provided evidence for the presence of two coding region polymorphisms
resulting in the amino acid substitutions Arg144Cys and Ile359 Leu [77–79]. In vitro expression
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studies suggested these changes were functionally significant [75]. Genotyping of patients undergoing
treatment with warfarin confirmed the functional importance of these polymorphisms [80–82].
The two polymorphisms (rs1799853 and rs1057910) form part of the CYP2C9*2 and CYP2C9*3 alleles.
Both variants are found at relatively high frequencies in white Europeans and this, together with their
well-established functional effects, has meant that they have been studied extensively in relation to
metabolism of a wide range of drugs. However, they are not the only clinically relevant polymorphisms,
and not even the most common variants in some ethnic groups.
5.2. Missense and Frameshift Variants in CYP2C9
CYP2C9*2 and *3 remain the best studied CYP2C9 alleles and are the most common variants
based on combined global allele frequencies available to date [83]. A large number of generally
less common alleles have also been identified; however, there is increasing data available about
frequencies in populations worldwide from ongoing exome and genome sequencing efforts. When
coding sequence polymorphisms are considered, the Exome Aggregation Consortium project (ExAC)
(http://exac.broadinstitute.org/) [84] provides comprehensive data on frequencies in a range of
populations for a large number of CYP2C9 single nucleotide variants (SNVs). There are limitations to
these data including the fact that over 50% of samples sequenced are of European ethnicity, although
African/African Americans, South Asians and East Asians are well represented here compared with
other data sources or small published population surveys. A summary of all CYP2C9 variants
associated with missense and frameshift mutations at “worldwide” frequencies down to 0.0001 based
on the ExAC data is provided in Table 2.
The summary of population frequencies in Table 2 shows the generally high frequencies of both
CYP2C9*2 and *3 compared with other alleles though with some important interethnic differences.
CYP2C9*3 is particularly common among South Asians and CYP2C9*2 is very rare among East Asians.
While other variants associated with missense and frameshift mutations tend to be rare, CYP2C9*8 and
CYP2C9*9 are more common than CYP2C9*2 and CYP2C9*3 in the African ethnicity group. Similarly,
and in line with published reports, CYP2C9*11 is approximately 10 times more common among
Africans compared with Europeans [85] though this allele and CYP2C9*12 appear to be the most
common European alleles after CYP2C9*2 and *3 [86–88]. As shown in Table 2 and elsewhere [89],
East Asians are very rarely positive for CYP2C9*2 and CYP2C9*3 is the most common variant allele.
In particular, this ethnic group is positive for a range of rare missense alleles with CYP2C9*52 the most
common after CYP2C9*3 [89]. South Indians are often positive for CYP2C9*2 and CYP2C9*3 but also
show an appreciable frequency of CYP2C9*14 (0.02). This allele is much rarer in other populations.
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rs1799853 p.Arg144Cys *2 c.430C>T 0.0914 0.1268 0.0235 0.0003 0.046
PolyPhen: probably damaging; SIFT:tolerated;
other:impaired S-warfarin metabolism
in vitro [77] and decreased dose in vivo [82]
rs1057910 p.Ile359Leu *3 c.1075A>C 0.0637 0.0688 0.0126 0.0338 0.1131
PolyPhen: possibly damaging; SIFT:
deleterious; other: impaired S-warfarin and
tolbutamide metabolism in vitro [78,79] and
decreased warfarin dose in vivo [82]
rs2256871 p.His251Arg *9 c.752A>G 0.0067 0.0002 0.0754 0.0001 0.0001
PolyPhen: probably damaging; SIFT:
deleterious; other: no effect on phenytoin
clearance in vivo [90]
rs7900194 p.Arg150His *8 c.449G>A 0.0052 0.0003 0.056 0.0001 0.0006
PolyPhen:benign; SIFT:tolerated; other:
increased activity towards tolbutamide
in vitro [91], decreased activity towards
phenytoin in vivo [90], decreased warfarin
activity in vitro and in vivo [92]
rs28371685 p.Arg335Trp *11 c.1003C>T 0.0038 0.0021 0.0214 0.0001 0.0019
PolyPhen: probably damaging; SIFT:
deleterious; other: decreased activity towards
warfarin in vivo and in vitro [87,91]
rs72558189 p.Arg125His *14 c.374G>A 0.003 0.0001 >0.0001 0.0001 0.0204
PolyPhen:benign; SIFT:deleterious; other:
very low activity in vitro towards
tolbutamide and warfarin [93]
rs9332239 p.Pro489Ser *12 c.1465C>T 0.0019 0.003 0.0006 0 0.0002
PolyPhen: possibly damaging; SIFT:
deleterious; other: decreased warfarin dose
requirement [88]
rs2837168 p.Asp360Glu *5 c.1080C>G 0.0012 <0.0001 0.0127 0 0
PolyPhen: probably damaging; SIFT:
deleterious; other: decreased activity towards
warfarin and diclofenac in vitro [94];
decreased phenytoin clearance in vivo [90]



















rs9332131 p.Lys273Arg(fsTer34) *6 c.818delA 0.0009 <0.0001 0.0105 0 0
Frameshift so inactivating; other: impaired
phenytoin clearance in vivo [95]
rs182132442 p.Pro279Thr *29 c.835C>A 0.0004 0.0005 * 0 0.0016 0.0001
PolyPhen:benign; SIFT:tolerated; other:
decreased activity in vitro with
tolbutamide [89]; decreased warfarin
clearance in vitro [93]
rs72558192 p.Thr299Ala *52 c.895A>G 0.0002 0 0 0.0035 0
PolyPhen: probably damaging; SIFT:
deleterious; other: mutation of known active
residue based on crystal structures of
flurbiprofen- and warfarin-bound
CYP2C9 [96], decreased activity in vitro with
tolbutamide [97]
rs72558187 p.Leu90Pro *13 c.269T>C 0.0001 0 0 0.002 0
PolyPhen:benign; SIFT:tolerated; other:
decreased activity in vitro with
tolbutamide [97]
rs7900194 p.Arg150Leu *27 c.449G>T 0.0001 0 0 0.0017 >0.0001
PolyPhen:benign; SIFT:tolerated; other:
decreased activity in vitro with
tolbutamide [97]; decreased warfarin
clearance in vitro [93]
* 0.0011 in Finns; Adapted from www.exac.org. SIFT: Sorting Intolerant From Tolerant.
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Frameshift variants are very rare in CYP2C9, but one variant CYP2C9*6 with a single base pair
deletion in exon 5 has been reported [95] (see Table 2). This variant will result in an inactive truncated
protein, and is seen at a frequency of approx. 0.01 in Africans and more rarely in Hispanic-Latinos,
but is very rare in other ethnicities.
Sequencing studies on CYP2C9 in some isolated populations have also been performed.
For example, in a study of American Indian and Alaska native people, CYP2C9*2 and *3 were found
at lower levels among the Yupik native people compared with other Alaskan residents, whereas the
East Asian CYP2C9*29 alleles showed a frequency of 0.02 in the Yupiks with two novel missense
variants, Met1Leu and Asn218Ile, seen at frequencies of 0.06 and 0.04 respectively [98]. It seems likely
that further novel alleles will be detected as additional population sequencing studies of this type
are performed.
Though the resequencing approach described above is the most informative as a means of studying
genotypes in isolated populations where novel alleles may be important contributors to phenotype,
there are also additional reports on the frequency of previously described polymorphisms in a number
of such populations. For example, CYP2C9*3 was reported to occur at an unusually high frequency
of 0.36 in a Malaysian aboriginal population, though CYP2C9*2, *4 and *5 were not detected [99].
In a survey of eight separate indigenous Mexican populations genotyped for CYP2C9*2, *3 and *6,
CYP2C9*2 was detected at low frequencies in two tribes at higher frequencies than those reported
for East Asians and CYP2C9*3 in six tribes with frequencies varying between 0.037 and 0.104 [100].
These findings are consistent with Asian-European admixture in these groups. Frequencies of known
CYP2C9 alleles in other indigenous North American populations are reviewed in detail in another
article in this issue [101]. There is also a recent review of frequencies in a range of populations
worldwide [102].
5.3. Functional Significance of CYP2C9 Missense Variants
The functional significance of many of the CYP2C9 variants listed in Table 2 has been investigated
widely, especially in the case of the common variants. The availability of detailed structural information
on CYP2C9 enables in silico prediction of the effect of amino acid changes from sequencing data.
However, only one of the variants shown in Table 2 (CYP2C9*52) results in mutation of a residue of
known to contribute to substrate binding (viz. Thr299Ala), based on the X-ray crystal structures of
flurbiprofen- and warfarin-bound CYP2C9 [96]. Several other rare variants (*28, *30, *52, *55, *57) listed
in the CYP alleles database (but not in Table 2) also fall within the active site, although no activity data
are available for the last three. The ExAC database provides predictions based on Sorting Intolerant
From Tolerant (SIFT), which makes predictions primarily from evolutionary sequence data together
with known effects of amino acid changes and PolyPhen, which uses both sequence homology and
structural predictions. These indices are useful but imperfect predictors of effect and do not necessarily
correlate completely [103], as discussed in detail elsewhere for CYP2C9 variants [104]. As summarized
in the effect column (Table 2), the two indices also do not correlate well in terms of predicting effects of
missense mutations on CYP2C9 activity. In addition to these in silico predictions, data on variant effects
are also available from in vitro expression studies and/or phenotypic studies in vivo involving either
pharmacokinetic measurements or pharmacodynamic endpoints such as warfarin dose requirement.
While it is acknowledged that binding residues may well differ between substrates (especially
those from different chemical classes), the molecular basis of the reduced activity observed for most
variants is not immediately apparent. Although there is evidence from in vitro studies to suggest that
the magnitude of the reduction in enzyme activity associated with some variants (e.g., CYP2C9*2)
may be substrate dependent (e.g., [22,93]), comparisons are not straightforward especially when
different enzyme sources are employed to generate kinetic data. It has been demonstrated that Km
values (and hence intrinsic clearances) for CYP2C9 substrates can vary between enzyme sources
(e.g., liver microsomes, recombinant CYP2C9 expressed in different cell lines) due to the inhibitory
effects of unsaturated long-chain fatty acids released during the course of an incubation [105]. Thus,
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while comparison of data obtained for variant CYP2C9 enzymes expressed in the same cell line is
expected to be valid, caution is necessary in the interpretation of data obtained for variants expressed
in different cell lines.
Almost all the relatively common variants listed in Table 2 result in decreased activity based on a
combination of in silico and in vitro or in vivo evidence. However, for the variants associated with the
CYP2C9*2, *8 and *9 alleles, the situation is less clear. For CYP2C9*2, it was proposed initially that the
Arg144Cys substitution alters the interaction with the electron donor cytochrome P450 oxidoreductase,
thereby reducing catalytic efficiency [106]. However, subsequent data indicated that alterations in the
P450 catalytic cycle, due to different degrees of coupling and uncoupling, were more likely responsible
for the lower activities of CYP2C9*2 and also CYP2C9*3 [107]. Structural changes in the CYP2C9*2 and
CYP2C9*3 proteins have been investigated using MD simulation [108–110]. The simulations variously
predicted that expansion of the active site volume (with reduced probability of substrate binding in a
catalytically favorable pose), increased interatomic distance between the site of metabolism and the
oxyferryl heme center, reduction in the size of the substrate entry channel, and impaired hydrogen
bonding with stabilizing amino acids contribute to the reduced activity of CYP2C9*2 and CYP2C9*3.
Although ligand-dependent conformational changes in CYP proteins are well accepted, differences in
the computational approaches adopted undoubtedly contribute to the different results observed in the
three studies [29]. For CYP2C9*3, the data are more consistent with almost all studies investigating
the activity of CYP2C9 variants finding that the Ile359Leu substitution associated with the CYP2C9*3
allele typically results in a greater than 80% reduction in the in vitro intrinsic clearances of CYP2C9
substrates. A recent X-ray crystal structure of CYP2C9*3 with losartan bound suggests that the effect
of the Ile359Leu substitution, located a distant 15 Å from the active site, is transduced to neighboring
I-helix residues that secondarily influence the β4 loop, which is important for substrate interactions
near the heme [37].
The activity of the CYP2C9*8-encoded enzyme is also relatively poorly understood. PolyPhen and
SIFT predict no effect of the Arg150His change on enzyme activity. In vivo studies on warfarin and
phenytoin clearance suggest decreased activity [90,92]. In vitro studies are limited but there is a
report of increased clearance and one of a 30% decrease in warfarin clearance [91,93]. The presence
of upstream polymorphisms in linkage disequilibrium with the coding variant could explain these
discrepancies and is discussed in detail below (Section 5.4).
CYP2C9*9 is predicted to be associated with decreased enzyme activity by both SIFT and PolyPhen.
Data on the variant is limited but no effect on phenytoin clearance in vivo was found [90] and the
available in vitro expression studies report slight decreases in warfarin and tolbutamide intrinsic
clearance that were not statistically significant [91,93].
Overall, as discussed above and summarized in Table 2, there is convincing evidence for decreased
activity from the CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11, CYP2C9*12 and CYP2C9*13 gene
products, and the CYP2C9*2 protein is also associated with impaired metabolism with at least some
substrates. However, evidence that other alleles listed in Table 2 such as CYP2C9*14, CYP2C9*27,
and CYP2C9*29 code for proteins that show functionally significant decreases in activity is based only
on in vitro studies in bacteria, insect cells and/or COS-7 cells [89,93,111]. The use of several substrates
that show good correlations in activity for the different variants in the same expression system is a
positive [93], but further evaluation of the relevance of these variants in vivo, especially in relation to
warfarin dosing, would be useful.
5.4. Variants in Non-Coding Regions
The ExAC project is mainly concerned with coding region variants but does provide some data
on non-coding variation in regions close to exons. However, all variants reported for CYP2C9 in these
regions are very rare (<0.0001) in each study population. There have been a number of studies of
polymorphism in upstream sequences covering the region up to approx. 10,000 bp upstream of the
translation start site. Overall, these indicate that coding region missense polymorphisms are a more
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important contributor to inter-individual variation in CYP2C9 activity, but a few interesting findings
in relation to the non-coding variants have also emerged.
Upstream region variants and their functional significance are most easily considered in
CYP2C9 haplotypes where there are no coding region polymorphisms present. A C>T variant at
−1188 (rs4918758) has been reported in several studies based in Europe, North America and Japan.
This variant is also seen in some haplotypes positive for rs1799853 (CYP2C9*2 allele). However, there is
no evidence that the variant at position −1188 is associated with altered transcription or warfarin dose
requirement [86,112,113]. A TG deletion at position −2663 (rs71486745) that lies within a putative
binding site for the transcription factor Nrf2 is relatively common in individuals negative for coding
region polymorphisms [86,112–114]. This variant is in linkage disequilibrium with the −1188 variant
mentioned above and a variant at position −3089 (rs12782374) which lies within another putative
transcription factor binding site, this time for YY1 [114]. Similar to the findings for the −1188 variant
alone, this haplotype did not affect warfarin or phenytoin dose requirement [86,112–114], but in vitro
transcription studies indicated that reporter gene constructs including this haplotype may be associated
with decreased responsiveness to both rifampicin and phenytoin when PXR and CAR, respectively,
are also co-transfected [113,114]. The lower CAR responsiveness was also localized to the −3089
position [114]. This polymorphism, which is seen at a frequency of 0.17 in white Europeans, may be of
limited relevance in terms of initial drug dosing, but could affect susceptibility to some DDIs.
Further upstream, a C>T at position −4302 (rs12251841) was detected in Mexicans but not in
non-Latino white Americans [113]. The variant appeared to be associated with lower constitutive
expression of the promoter region. A further study on phenotyped human livers and patients treated
with warfarin detected a variable number of tandem repeats (VNTR) sequence at position −3979
approx. Three patterns that were termed short, medium and long were identified. The medium repeat
pattern was the most common and taken as the reference sequence [115]. The short allele appeared to
be associated with decreased levels of CYP2C9 transcription in the liver, based on allelic imbalance
studies and reporter gene assays. In addition, homozygosity for the short allele was associated with a
lower warfarin dose but the overall effect on dose of this variant was less than that seen with CYP2C9*2
and *3 and was not significant in a multiple regression model [115].
Several upstream variants that are part of a haplotype that also includes rs1057910, which codes
for the missense mutation in the CYP2C9*3 allele, have also been detected [116]. These variants
were originally thought to be associated directly with decreased CYP2C9 activity. As discussed
elsewhere [86,112], there is decreased transcriptional activity in reporter gene studies [113,116] but this
decrease is on the order of 50% whereas the effect of the Ile359Leu amino acid substitution is larger in
terms of overall effect on enzyme activity.
As discussed above, the overall enzyme activity associated with the CYP2C9*8 allele is still not
very clear, with in silico predictions suggesting no effect of the Arg150His substitution on enzyme
activity, in vitro studies producing contradictory findings, and in vivo studies suggesting decreased
activity. An upstream polymorphism −1766 T>C shows strong linkage disequilibrium with rs7900194
in African-Americans and this haplotype also includes the −1188 T>C variant discussed above.
Allele imbalance and luciferase reporter gene studies indicate that a−1188C–1766C sequence results in
lower levels of transcription compared with the −1188T–1766T sequence [117]. Polymorphisms in the
upstream sequence may, therefore, be a better explanation of the apparent decreased in vivo CYP2C9
activity in individuals positive for CYP2C9*8 than the missense mutation.
A sequencing study on CYP2C9 variation in relation to warfarin dose requirement in
African-Americans reported that a variant in intron 3 (rs7089580) was associated with a high warfarin
dose requirement. This variant was in linkage disequilibrium with several other intronic variants
and it was suggested that one of these might be within a transcription factor binding site [118]. In a
genome-wide association study (GWAS) on warfarin dosing in African-Americans, an upstream
CYP2C9 variant rs12777823 exhibited a significant association with dose requirement in addition
to CYP2C9*2 and CYP2C9*3 [117]. This variant is upstream of CYP2C18, which is located quite a
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long distance from CYP2C9 on chromosome 10. As discussed below, there is extensive long-range
linkage disequilibrium within the CYP2C gene cluster and this variant may be associated with other
polymorphisms closer to CYP2C9.
5.5. Linkage Disequilibrium with Other CYP2C Genes
CYP2C9 is part of the four-gene CYP2C cluster on chromosome 10. CYP2C9 is flanked upstream
by CYP2C19 and downstream by CYP2C9 with CYP2C18 further upstream of CYP2C19. A number of
studies have investigated linkage disequilibrium between common SNPs in CYP2C8 and CYP2C9 with
more limited investigation of relationships with CYP2C19. Linkage disequilibrium between CYP2C9
and CYP2C8 was first reported in 2002 [119] when it was shown that almost all individuals positive
for CYP2C9*2 were also positive for CYP2C8*3, an allele with two nonsynonymous mutations that
is believed to be associated with decreased activity. In a more detailed study involving a range of
different populations [120], it was reported that 90% of European and South West Asian alleles that
are positive for the CYP2C9*2-associated Cys144 are also positive for the two CYP2C8*3-associated
amino acid substitutions. Individuals positive for Cys144, but negative for the two CYP2C8*3 variants,
are seen occasionally in populations where CYP2C9*2 is common (Table 2) but the frequency of this
haplotype is low in the populations examined [120]. In view of the overlap in substrate specificity
between these two P450s with certain substrates such as ibuprofen and arachidonic acid, this finding
is of considerable interest in terms of potential clinical impact.
The relationship between CYP2C9 and CYP2C19 genotypes has been examined in a single
study [121]. This study confirmed the existence of a number of rare CYP2C9 variants in Japanese
subjects (Table 1), and also found that two upstream CYP2C9 haplotypes (Section 5.4) were in
linkage disequilibrium with the loss of function CYP2C19*2 and CYP2C19*3 alleles respectively.
These upstream CYP2C9 variants are believed not to affect CYP2C9 expression so it is unlikely that
there will be any joint impact on drug metabolism. However, these findings show that linkage
disequilibrium within the CYP2C region extends from CYP2C9 upstream to CYP2C19 and the
possibility that impaired function for both enzymes could be seen in some ethnic groups. As discussed
in Section 5.4, a polymorphism in CYP2C18 that is further upstream of CYP2C9 than CYP2C19 appears
to affect warfarin dose requirement in African-Americans [117].
6. Clinical Significance of CYP2C9 Polymorphisms
6.1. Coumarin Anticoagulants
In terms of clinical significance of CYP2C9 polymorphisms, the most well studied example is the
relationship between warfarin dosing and genotype. There are also a number of studies concerned with
other coumarin anticoagulants. As discussed in Section 4, CYP2C9 is the major P450 that contributes to
hydroxylation of the key active enantiomers for these compounds. Initial studies showing an effect of
CYP2C9 genotype on warfarin dose involved studies on patients requiring unusually low doses [81,82],
but this effect was confirmed subsequently in studies on patients of European ethnicity taking a
range of warfarin doses [122–125]. A significant contribution of the CYP2C9*2 and *3 variants to dose
requirement has also been shown by several GWAS [126–130]. A meta-analysis of studies involving
multiple ethnicities showed significant effects for CYP2C9*2 on dose requirements in European and
African-American populations with all ethnic groups studied to date demonstrating an effect for
CYP2C9*3 [131]. Bleeding events due to warfarin have also been studied in relation to CYP2C9
genotype and the foregoing meta-analysis found an association only for patients with two copies of
CYP2C9*3 [131]. The overall contribution of CYP2C9 to warfarin dose requirement is considered in
more detail in Section 7, which considers dosing algorithms and contributions by other genetic and
non-genetic factors.
For acenocoumarol and phenprocoumon, data on the relationship between CYP2C9 genotype
and dose requirement is more limited compared with warfarin. Though there are reports that
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CYP2C9 genotype is less important as a determinant for phenprocoumon dosing than warfarin or
acenocoumarol [132], a large study which studied both acenocoumarol and phenprocoumon dosing in
parallel reported that CYP2C9 genotype explained 4.5% of dose variation for acenocoumarol and 4.6%
for phenprocoumon [133]. This CYP2C9 contribution to dose requirement is lower than most reports
for warfarin. Algorithms incorporating the CYP2C9 data for phenprocoumon and acenocoumarol
dosing were developed and used in a randomised controlled trial which failed to show significant
benefit for genotype-guided dosing [134] with these drugs, but generally data on the importance of
CYP2C9 genotype to non-warfarin coumarin anticoagulant treatment remains sparse.
6.2. Sulfonylureas
Two large studies have evaluated the relevance of CYP2C9 genotype to response to sulfonylurea
treatment. The earlier of these was concerned with tolbutamide and reported that CYP2C9*3 carriers
were prescribed significantly lower doses of this drug than homozygous wild-type patients [135].
A second reported a better response to treatment with a number of different agents, in those carrying
CYP2C9*2 or *3 alleles though the majority of these patients were prescribed glicazide and none were
taking tolbutamide [136]. There are also limited reports that individuals carrying CYP2C9 variant
alleles are at increased risk of hypoglycaemia [137–139].
6.3. Nonsteroidal Antiinflammatory Drugs
Unlike the examples in the two previous sections, response to NSAIDs is less easily measured and
the majority of studies on CYP2C9 pharmacogenomics in relation to this drug class are concerned with
adverse events. One study did investigate efficacy in the context of using celeboxib to prevent colorectal
adenoma and found carriage of CYP2C9*3, but not CYP2C9*2, was associated with increased protection
against adenoma in those taking high doses though the overall effect was small [140]. For adverse
events, the main issues that have been investigated are gastrointestinal bleeding, hepatotoxicity and
susceptibility to cardiovascular events. The overall contribution of CYP2C9 to the metabolism of
drugs in this class varies and its contribution to clearance of a number of agents, especially those
implicated in cardiovascular events, is likely to be insufficient to show important pharmacogenomic
associations [141]. However, a number of NSAIDs including ibuprofen, flurbiprofen and celecoxib
may be sufficiently CYP2C9-dependent in their clearance for genotype to be relevant. There are several
reports suggesting that carriage of CYP2C9 variants increases the risk of gastrointestinal bleeding to
NSAIDs generally [142–144] with the highest risk relating to CYP2C9*3. However, individual NSAIDs
have not been investigated in a systematic manner. Several NSAIDs are associated with drug-induced
liver injury and the best studied member of the class in this context is diclofenac. An increased
frequency of CYP2C9 variant alleles was not detected in diclofenac-induced liver injury cases [145],
either genotyping directly for CYP2C9*2 and *3 or in a larger GWAS [146].
6.4. Phenytoin
Similar to warfarin, phenytoin has a narrow therapeutic index with pharmacokinetic variability
due to CYP2C9 polymorphisms well established for both CYP2C9*2 and CYP2C9*3 [147]. Effects on
the central nervous system are the most common symptom of high plasma drug levels but there is also
an increased risk of serious skin rash [148]. Data on the relevance of CYP2C9 genotype to neurological
toxicity are limited but there is a report of such toxicity in a patient with a homozygous CYP2C9*2
genotype [149]. There is also a risk of serious skin rash with phenytoin [148]. The genetic basis of
this adverse reaction has been investigated by GWAS in an Asian population and a genome-wide
significant signal with CYP2C9*3 reported [150]. Hepatotoxicity reactions are also seen occasionally
with phenytoin [151], but the genetic basis for these remains unclear.
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6.5. Miscellaneous
The relevance of common CYP2C9 polymorphisms to a range of different drug substrates in
addition to the major groups discussed above has been investigated. In the case of losartan where
both the parent drug and E-3174, the metabolite generated by CYP2C9, are active, the ratio of losartan
to E-3174 is genotype-dependent when the effect of CYP2C9*2 and *3 is assessed [152]. There is
limited data suggesting that those homozygous or possibly heterozygous for CYP2C9*3 show a poorer
anti-hypertensive response [153]. On the other hand, for candesartan and irbesartan where active
metabolites are not generated, those positive for CYP2C9 variants are at risk for hypotension [53,154].
Bosentan is an endothelin receptor antagonist used for treatment of pulmonary arterial
hypertension. There is evidence that CYP2C9 contributes to its oxidative metabolism [155]. It is well
established that bosentan can cause drug-induced liver injury and patients taking this drug undergo
routine transaminase monitoring as a result [156]. Two recent studies suggest that CYP2C9 variant
alleles, particularly CYP2C9*2, increase the risk of developing hepatotoxicity with this drug [157,158].
The effect sizes seen are modest and further work is needed, particularly because CYP2C9 is not the
only P450 isoform contributing to metabolism [155].
CYP2C9 contributes to arachidonic acid metabolism converting it to EETs [159]. EETs have
vasodilatory and antiinflammatory effects that may be relevant to physiological processes including
angiogenesis and regulation of vascular tone. Although CYP2C8 and CYP2J2 also carry out these
reactions and may have a more important role in EET metabolism extrahepatically, CYP2C9 is also
likely to contribute. As described in more detail elsewhere [56,160], a number of case-control candidate
gene studies on associations between CYP2C9 genotypes and susceptibility to coronary heart disease,
coronary artery disease, myocardial infarction and hypertension have been performed. To date,
these studies have yielded rather contradictory results. GWAS on cardiovascular diseases have
so far failed to detect significant signals for CYP2C9, so despite the biological plausibility of EET
production being relevant to disease risk and a relatively large number of studies, evidence for a
pharmacological effect in vivo is limited.
7. Warfarin Dosing Algorithms
Clearly, CYP2C9 genotype is an important predictor of warfarin dose requirement. However,
a number of other factors contribute to dose, including genotype for vitamin K epoxide reductase
(VKORC1), which encodes the warfarin target, patient age and patient weight or height.
There have been a number of estimates of the contribution of CYP2C9 genotype to warfarin dose
requirement among Europeans with initial results ranging from 6 to 19% [122,161,162]. For other ethnic
groups where the range and frequency of CYP2C9 variants is different, the contribution of CYP2C9 is
less well understood but, where known, tends to be lower mainly because variants associated with
low activity are rarer in most non-European groups. When the other parameters mentioned above are
added, typically the percentage of overall variation in dose requirement that can be estimated is in the
order of 50%. Other genes in addition to CYP2C9 and VKORC1, such as CYP4F2, which contributes to
vitamin K metabolism, are also relevant to warfarin dose requirement but their overall contribution is
lower, so these are generally less useful as predictors for dosing.
The earliest warfarin dosing algorithms incorporating genetic factors included only CYP2C9
genotype [122,161]. Once VKORC1 was also shown to be of relevance to dosing, algorithms
incorporating this second genetic factor were developed [163–171]. These algorithms were developed
and tested on relatively small patient groups, though overall they were not too dissimilar. One of
these algorithms was developed using data from a relatively large number of American patients and is
web-based (www.warfarindosing.org) [171]. To further improve ability to predict dose requirement
and to cover a wider range of ethnicities, a joint project involving a large number of researchers
worldwide (International Warfarin Pharmacogenetics Consortium (IWPC)) used clinical and genetic
data on 4043 patients treated with warfarin to develop a more definitive warfarin dosing algorithm
which was then tested on a replication cohort of 1009 patients [172]. This was an important step
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forward in developing a clinically useful algorithm for warfarin dosing, but limitations included an
over-representation of European patients and the fact that the only genotypes considered were those
for common variant alleles in CYP2C9 and VKORC1. It was also uncertain exactly how an algorithm
predicting the stable dose of warfarin should be implemented clinically. Further refinements of the
IWPC algorithm have subsequently been made. One refinement introduces a “dose-revision algorithm”
which involves initiation of treatment based on the IWPC algorithm-calculated dose followed by use
of a new algorithm that incorporates genetic factors, INR value and clinical factors on day 4 or 5 of
treatment [173]. Another uses an “initiation dose” algorithm derived from the IWPC algorithm, but
introduces an additional term to increase the dose on days 1 to 3 of treatment [174]. Few currently
available warfarin dosing algorithms include genetic factors other than the common CYP2C9 and
VKORC1 variants, but modification of existing algorithms to include CYP4F2 genotype and a range of
rarer CYP2C9 alleles has been suggested to improve stable dose prediction [175,176]. This has also
been implemented in the web-based warfarin dosing calculator [177].
Though the IWPC algorithm was developed to cover a wide range of ethnic groups,
dosing algorithms have also been developed specifically for specific ethnic groups [88,178–181].
Children occasionally require treatment with coumarin anticoagulants. Two studies suggest that
the algorithms developed for adults are not predictive of dose requirements in this group and have
proposed alternative algorithms [182,183].
Early clinical trials assessed the use of genotype and other patient-related factors to set
initial warfarin dose [167,184–188]. In general, these early studies found no advantage for a
genotype-determined dose, but power to detect all genetic effects appears to have been limited.
One of these studies involved CYP2C9 genotypes only and found improved time to stable INR and
higher percentage of time within therapeutic range in genotype-guided dose cases compared with
controls receiving normal treatment [184]. Another study showed that providing information on
CYP2C9 and VKORC1 genotype to the prescriber resulted in better outcomes for warfarin treatment.
However, genotype data was only available approx. 32 days after the start of treatment, which is an
important limitation [185].
The first large randomized control trial (RCT) involved 504 cases treated with a
pharmacogenetics-guided dose and 1911 controls given standard dosing [189]. This study showed
that the pharmacogenetic-guided dosing group had a higher percentage of patients within therapeutic
INR range at two time points and fewer patients showing serious adverse events or very low or high
INR values.
Outcomes of two further RCTs were reported in 2013. These RCTs, termed EU-PACT and
COAG, were based in Europe and the USA respectively and reported different findings [190,191].
EU-PACT found that patients who received a genotype-guided warfarin dose remained in the target
therapeutic range for a significantly longer time in the first three months of treatment compared with
patients treated with a standardized conventional dosing regimen. COAG reported no improvement
in time within therapeutic range in the first 4 weeks of treatment. These conflicting findings may be
due to some differences in study protocol and the participating patients. In particular, the dosing
algorithms and genotyping assay protocols were different and in addition COAG included a significant
number of African-American patients whereas EU-PACT involved white Europeans only. EU-PACT
used a modified IWPC initiation loading dose [174] with a further day 4 or 5 modification [173].
COAG used a modified version of the web-based warfarin dosing calculator algorithm [171],
which gives the predicted maintenance dose, but ignored the effect of CYP2C9 in those patients
positive for CYP2C9 variant alleles for the day 1 dose only. The study also applied a day 4 or 5
dose-refinement algorithm [173]. The two studies were different in the treatment of the control arm,
with EU-PACT using a standardized approach but COAG using a clinical dosing algorithm that
included factors such as age. All patients in the genetics arm of EU-PACT were genotyped before the
first dose of warfarin, whereas genotype data was available for only 45% of COAG patients in the
genotyping arm at the first dose (though by day 2 this information was available for 94% of patients).
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As suggested elsewhere [192], due to use of a maintenance dose algorithm to determine initial dose,
it is unlikely that steady state was achieved in most COAG patients by day 4. This would result in
limited changes in INR and make the dose-refinement algorithm less useful. It has also been suggested
that the benefit of genotyping seen in EU-PACT could be due to the dosing protocol used for the
control group, which included only limited initial dose loading [193]. Very recently, the outcome of
a further RCT, the GIFT study, has been reported [194]. This study used the web-based warfarin
dosing calculator algorithm with the CYP4F2 modification discussed above in a predominantly white
American population. The genotype-guided dose arm received the calculated dose for 11 days after
initiation and showed a better outcome compared with a control group dosed with a clinically guided
algorithm in relation to several parameters including INR above four, bleeding and death. The overall
findings appear fairly consistent with EU-PACT. Though the study included 1650 patients, they were
older than those in EU-PACT and COAG and undergoing arthoplasty. Consequently, they were
not necessarily typical of most patients initiating warfarin treatment so there are some limitations.
Similar to EU-PACT, GIFT had genotype data available prior to initiation of dosing.
An important issue emerging from COAG was poorer outcomes in the genotyped
African-Americans compared with the control group. This may reflect the fact that CYP2C9 genotyping
was only for the *2 and *3 alleles. As discussed in detail in Section 5.2, other CYP2C9 alleles such
as CYP2C9*5, *6, *8 and *11 are likely to be relevant to dosing in African-Americans. There are
also additional VKORC1 variants that may be relevant to dosing [118]. An algorithm specific to
African-Americans that includes provision for additional CYP2C9 and VKORC1 alleles has been
developed and appears to predict dose requirement more accurately than the IWPC algorithm [88].
The web-based warfarin dosing calculator algorithm has also been modified to include the common
African-American CYP2C9 and VKORC1 variants and this also led to improved dose prediction [177].
Additional modifications that take into account other CYP2C9 variants seen internationally (see
Section 5.2) may be valuable for these algorithms.
Comparison of the warfarindosing.com and IWPC algorithms suggests that both predict
comparable warfarin doses [193]. A recent study found that in patients requiring 7 mg or greater
per day, a range of algorithms including those from warfarindosing.org and IWPC under-predicted
maintenance dose requirement [195]. The underlying reason for this issue remains unclear, but it has
been suggested that it could reflect the complexity of the blood clotting cascade. It is not clear what
further modifications to algorithms can be made to improve this issue. Though this limitation may lead
to delayed achievement of target INR in a minority of patients, the algorithms seem particularly useful
in preventing excessively high INR values during the early stages of anticoagulation in patients with a
low maintenance dose requirement. High INR values (>4) are a risk factor for bleeding, particularly in
elderly patients [196] and warfarin related-adverse drug reactions of this type are a common cause of
hospital admission [197].
Although not all RCTs to date have provided unequivocal evidence that genotyping for
CYP2C9 and VKORC1 is beneficial prior to dosing with warfarin, support for genotyping has
been obtained in a large RCT which compared warfarin and the direct-acting anticoagulant
(DOAC) edoxaban [198]. This study did not genotype at initiation of treatment but was able to
demonstrate a clear relationship between the presence of CYP2C9 or VKORC1 variant alleles and
early bleeding. Approximately 5000 patients were included in the warfarin treatment arm enabling
this important endpoint to be analyzed directly. With the development of edoxaban and other
DOACs, patients needing oral anticoagulants are increasingly being prescribed these drugs in place
of warfarin. This may limit the further application of genotyping to warfarin prescribing though,
as discussed recently, there is still a need to comprehensively understand the risk-benefits of these new
agents [192] and warfarin is still likely to remain a widely-prescribed drug, especially if appropriate
dosing algorithms and genotyping strategies can be incorporated in its routine use.
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8. Contemporary Translational Efforts
8.1. Pre-Emptive Genotyping
Despite substantial efforts from many research teams world-wide, the incorporation of
genotype-guided dosing for CYP2C9-related outcomes is far from routine. However, in North America
at least, several large teaching hospitals and research institutions (e.g., Vanderbilt, St. Jude, Mayo Clinic)
are actively evaluating the impact of prospective genotyping for an array of pharmacogenes,
as is evident from other contributions to this Special Issue. Justification for this comes, in part,
from the realization that in any given patient population the proportion that possess an ‘actionable
pharmacogene’ is very high, exceeding 90% [55,199]. This term has been coined by the Clinical
Pharmacogenetics Implementation consortium (CPIC), which has the goal ‘to help clinicians
understand how available genetic test results should be used to optimize drug therapy’ [200].
CYP2C9 has been identified by CPIC as a key component of several level A or B drug–gene pairs
wherein prescribing action based on pharmacogenetic information is recommended for therapy with
phenytoin, warfarin and celecoxib [201].
8.2. The Problem of Variants of Uncertain Significance
However, while the discovery of genetic variation in pharmacogenes continues at a substantial
pace, aided by advances in DNA sequencing technologies and the investigation of more targeted
disease and under-served ethnic populations, there are several well-recognized barriers that need to be
overcome to ensure widespread clinical implementation of pharmacogenomics [202]. A key challenge
is the provision of clear, unambiguous guidance to health care providers in use of pharmacogenomic
information. This is difficult enough for well-studied alleles such as CYP2C9*2 and CYP2C9*3, but the
paucity of information on the functional consequences of rarer pharmacogene alleles and diplotypes
is a large impediment to providing comprehensive guidelines to the medical community. The true
magnitude of these unmet needs becomes clear when one considers the totality of rare variation that
will be identified when comprehensive medical genetic screens become the norm [203]. Exome and
genome sequencing is already widely employed as a research tool, and the genome Aggregation
Database, which includes 123,136 exomes and 15,496 whole genomes [84], has entries for over 400
rare missense and loss-of-function SNPs (minor allele frequency (MAF) < 0.05) in CYP2C9, 227 of
which were singletons. Undoubtedly, as genome-wide sequencing of CYP2C9 continues, many
more ‘privileged’ SNPs will be identified. This issue is not confined to CYP2C9, as a recent study of
rare variation in CYP genes illustrates, where 730 novel non-synonymous variants in 12 CYPs were
discovered in the exomes of ~6500 individuals [204]. These variants were individually rare, but ~10% of
individuals carried at least one potentially deleterious novel variant at one of these 12 loci. These genes
also contain previously known rare (MAF < 0.5–1%) variants whose functional consequences remain
unclear. These results, obtained from a limited number of individuals relative to the number of patients
who will ultimately be genotyped, raise serious questions about how to deal with this avalanche of
information for the so-called ‘variants of uncertain significance’ [205]. One might argue that because
nearly all identified new coding variation will be found in the heterozygous state, the impact might
only be significant for those null or near-complete loss of function allele. However, even moderate




Currently, the best methods for determining the impact of a newly identified coding variant
fall into two categories. First, traditional biochemical assays, such as S-warfarin and S-flurbiprofen
metabolite assays can reveal the functional consequences of CYP2C9 variants, usually by comparison
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of their in vitro intrinsic clearance parameters, Vm/Km. However, these assays are limited in scale
to at most hundreds of coding variants and so are unable to deal with the massive numbers of
variants that will be revealed in the extant human population. Second, numerous algorithms alluded to
earlier (e.g., SIFT, PolyPhen etc.) have been used to assign a probable function to missense mutations.
These algorithms have the advantage of being scalable such that they can describe the consequences
of any CYP2C9 (or other pharmacogene) variant. However, computational approaches are of limited
value at present, often producing incorrect or conflicting results. This problem is illustrated by an
analysis of the common I359L (CYP2C9*3) polymorphism in CYP2C9. CYP2C9*3 encodes arguably the
most important deleterious CYP2C9 variant because of its relatively high MAF (~7% in Caucasians)
and the in vitro and in vivo experimental data that demonstrate ~90% loss of function for this allele.
However, the non-synonymous amino acid change is extremely conservative and the PolyPhen 2
score is only 0.02, which is predictive of a benign mutation. While more contemporary algorithms
offer some predictive improvements [206], what the field needs is a uniform experimental approach
that provides an ‘impact score’ that describes the functional consequences of every possible missense
variant at every position in each pharmacogene [207]. Such an approach would allow us not only to
make predictions about the alleles that have already been observed, but also to generate a look-up
table that can be employed to interpret new alleles discovered in the future.
9.2. Large-Scale Functional Assays
With recent advances, especially around deep mutational scanning (DMS), large-scale functional
annotation of pharmacogenes is a realizable goal. DMS is a relatively new technology that can
quantify the effect of hundreds of thousands of variants of a protein of interest in parallel and at low
cost [208–210]. Rather than assaying individually chosen variants for their functional consequences,
this method can measure the activity or stability of each of many variants of a protein in a single
experiment. DMS uses a coupled genotype–phenotype system, where a library encoding protein
variants is introduced into an appropriate host cell. A selective pressure is applied to this library
of variants, altering the frequency of each variant depending on its level of activity or stability.
High-throughput DNA sequencing is used to characterize the frequency of each variant throughout
the selection, and the change in frequency is used to calculate a functional score. Variants that are
depleted after selection have low functional scores whereas variants that are enriched after selection
have high functional scores. The result is a large-scale protein functional data set, identifying important
positions, as well as activity-enhancing and loss-of-function mutations. Studies are underway to
catalog the effects of the 10,290 possible coding-region variants in CYP2C9 [211]. Successful completion
of this goal will provide not only an invaluable resource to guide decision-making at the clinical
level, but also elucidate fundamental biochemical relationships between P450 structure, catalysis and
enzyme stability.
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